Atrium Therapeutics, Inc. Common Stock (RNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atrium Therapeutics, Inc. Common Stock (RNA) has a cash flow conversion efficiency ratio of -0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.25 Million) by net assets ($207.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Atrium Therapeutics, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Atrium Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Atrium Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Atrium Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atrium Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wismilak Inti Makmur Tbk
JK:WIIM
|
0.040x |
|
China Ecotek Corp
TW:1535
|
0.170x |
|
TerrAscend Corp
F:TED
|
0.081x |
|
Com2uS Corporation
KQ:078340
|
0.009x |
|
Re Max Holding
NYSE:RMAX
|
-0.509x |
|
Studsvik AB
ST:SVIK
|
0.140x |
|
HMH Holding Inc. Class A Common Stock
NASDAQ:HMH
|
0.010x |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Atrium Therapeutics, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Atrium Therapeutics, Inc. Common Stock from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Atrium Therapeutics, Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $207.29 Million | $-41.13 Million | -0.198x | +6.03% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treat… Read more